$0.85
-0.15 (-14.58%)
Open$0.85
Previous Close$1.00
Day High$0.87
Day Low$0.78
52W High$2.44
52W Low$0.73
Volume—
Avg Volume3.91M
Market Cap37.55M
P/E Ratio—
EPS$-0.19
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,070.4% upside
Current
$0.85
$0.85
Target
$44.00
$44.00
$29.80
$44.00 avg
$55.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.74M | 5.58M | 6.05M |
| Net Income | 1.11M | 1.28M | 1.11M |
| Profit Margin | 19.3% | 22.9% | 18.3% |
| EBITDA | 2.54M | 2.28M | 2.52M |
| Free Cash Flow | 874.9K | 1.03M | 1.03M |
| Rev Growth | +19.1% | +13.5% | +5.7% |
| Debt/Equity | 1.60 | 1.67 | 1.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |